Background: Type 2 innate lymphoid cells (ILC2s) represent an important type 2 immune cell. Glucocorticoid regulation of human ILC2s is largely unknown. Objective: We sought to assess steroid resistance of human blood and airway ILC2s from asthmatic patients and to examine its mechanism of induction. Methods: We studied human blood and lung ILC2s from asthmatic patients and control subjects using flow cytometry and ELISA. Results: Dexamethasone inhibited (P 5 .04) chemoattractant receptor-homologous molecule expressed on T H 2 lymphocytes and type 2 cytokine expression by blood ILC2s stimulated with IL-25 and IL-33. However, it did not do so when ILC2s were stimulated with IL-7 and thymic stromal lymphopoietin (TSLP), 2 ligands of IL-7 receptor a. Unlike blood ILC2s, bronchoalveolar lavage (BAL) fluid ILC2s from asthmatic patients were resistant to dexamethasone. BAL fluid from asthmatic patients had increased TSLP but not IL-7 levels. BAL fluid TSLP levels correlated (r 5 0.74) with steroid resistance of ILC2s. TSLP was synergistically induced in epithelial cells by IL-13 and human rhinovirus. Mechanistically, dexamethasone upregulated ILC2 expression of IL-7 receptor a, which augmented and sustained signal transducer and activator of transcription (STAT) 5 signaling by TSLP. TSLP induced mitogen-activated protein kinase kinase (MEK), c-Fos, inhibitor of DNA binding 3, phosphorylated signal transducer and activator of transcription (pSTAT) 3, and pSTAT5, molecules
Innate lymphoid cells (ILCs) represent a lineage of lymphoid cells that diverge from lymphoid cells (T and B cells) of the adaptive immune system at an early developmental stage because of high expression of inhibitor of differentiation 2 (ID2). 1 ILCs are akin to natural killer cells and readily respond to a tissue insult or injury. Type 2 innate lymphoid cells (ILC2s) are an important source of type 2 cytokines. They produce relatively high quantities of IL-4, IL-5, and IL-13, among other cytokines. They are most prevalent in tissue, especially mucosal tissue.
A growing number of studies have implicated ILC2s in the pathogenesis of allergic diseases and in defense against parasites. ILC2 numbers were increased in blood from patients with many allergic diseases: allergic rhinitis, 2 asthma, 3 eosinophilic sinusitis, 4 eosinophilic esophagitis, 5 and atopic dermatitis. 6 We reported an increased frequency of ILC2s in bronchoalveolar lavage (BAL) fluid from patients with allergic asthma. 7 An increased frequency of ILC2s was also reported in the sputum of asthmatic patients. 8 By producing high quantities of IL-5 and IL-13, ILC2s are likely to contribute to eosinophilia and airway hyperreactivity. T H 2 cells and T H 2-driven eosinophilia are usually sensitive to inhibition by steroids (glucocorticoids), although they can become steroid resistant under certain circumstances. [9] [10] [11] In a subgroup of patients, asthma does not satisfactorily respond to high-dose inhaled and oral steroids. 12 These patients are labeled as having severe refractory asthma. These patients continue to manifest eosinophilia in the blood and airways while taking steroids. The mechanism of steroid resistance in this type 2 inflammation is not fully understood. Recently, Kabata et al in a thymic stromal lymphopoietin (TSLP)-dependent manner. 13 This study suggested that ILC2s could contribute to steroid resistance in patients with type 2 inflammatory diseases. In contrast, Walford et al 4 reported that both mouse and human ILC2s were sensitive to steroids. Treatment with steroids caused apoptosis of ILC2s in vitro and in vivo. The effect of steroids on ILC2s, especially airway ILC2s from patients with asthma, is unknown. Because the number of ILC2s is increased in asthmatic patients, we asked in this article whether ILC2s developed steroid resistance in patients with refractory asthma.
METHODS

Human subjects
We studied blood and BAL fluid ILC2s from allergic asthmatic patients, control subjects with disease, and healthy donors. Allergic asthmatic patients and control subjects with disease were recruited from the outpatient clinics at National Jewish Health. Bronchoscopy and BAL were performed as a part of their clinical work-up for poorly controlled asthma. None of the control subjects with disease met the American Thoracic Society diagnostic criteria for asthma. The protocols for blood and BAL studies of lymphoid cells from asthmatic patients and control subjects with disease were approved by the institutional review board. Written informed consent was obtained from each participant. Healthy donors were recruited from the blood bank of National Jewish Health. Asthmatic patients and control subjects with disease maintained their controller medications at the time of bronchoscopy. Demographic and clinical characteristics of asthmatic patients and control subjects with disease are shown in Table I .
Isolation of PBMCs and lineage-negative cells, culture, and flow cytometry for ILC2s
PBMCs were isolated from EDTA-treated blood by means of density centrifugation with Ficoll-Hypaque. PBMCs were cultured in RPMI 1640 plus 10% FBS in the medium alone or with the cytokine combo (as indicated in the text) with dexamethasone (10 27 mol/L) or vehicle (0.1% ethanol), as described previously. 14 The following cytokines were used at 20 ng/mL: IL-2, IL-7, IL-25, IL-33, and TSLP (all from PeproTech, Rocky Hills, NJ). The concentration of the allergen extract Aspergillus species (Greer Labs, Lenoir, NC) in the PBMC culture was 5 mg/mL. 
Airway epithelial cell culture and real-time PCR
Freshly isolated epithelial cells from bronchial brushings were obtained from patients with allergic asthma and cultured at the air-liquid interface, as described previously. 15 Confluent cells were cultured with IL-13 (10 ng/mL), IFN-g (10 ng/mL), LPS (1 mg/mL; Sigma-Aldrich, St Louis, Mo), polyinosinic-polycytidylic acid (poly-IC; 50 ng/mL), or human rhinovirus-16 (8 3 10 4 tissue culture infective dose/well) for 24 hours. Isolation of mRNA and real-time PCR were performed, as described previously. 16 The primers for TSLP were as follows: forward, 59-ACCTTCAATCCCACC GCCGGC-39; reverse, 59-GGCAGCCTTAGTTTTCATGGCGA-39 (synthesized by Integrated DNA technologies, Coralville, Iowa).
ELISA for cytokines
Levels of IL-7 and TSLP in BAL fluid from asthmatic patients and control subjects with disease and TSLP from epithelial cell cultures were measured by means of ELISA. IL-5 levels were measured in the culture supernatant from Lin 2 cells. The IL-5 ELISA kit was from Thermo Fisher Scientific (Waltham,
Statistical analyses
Comparisons between study groups were done with the Mann-Whitney U test, unless otherwise stated. Comparisons among multiple study groups were performed with the Kruskal-Wallis test. The Pearson correlation coefficient was used to calculate correlation coefficients.
RESULTS
Study subjects
We studied blood and BAL fluid from a total of 50 asthmatic patients and 35 control subjects with disease. We also obtained blood from the National Jewish Health Blood Bank for Research, which recruits healthy donors under an institutional review board. Demographics and disease characteristics for the patient populations are shown in Table I .
Effect of dexamethasone on blood ILCs
We examined the effect of dexamethasone on survival of blood ILCs. To this goal, we cultured PBMCs in medium and with a combination of the cytokines IL-2, IL-7, and IL-33 with and without dexamethasone for 5 days. Cell death was initially analyzed by gating for live and dead cells by using flow cytometry with forward and side scatter. We observed a modest increase in dead cells in cultures with dexamethasone (see Fig E1 in this article's Online Repository at www.jacionline.org). There were more dead cells in cultures stimulated with cytokines, which perhaps reflects activation-induced cell death. The live cell population was gated for further analysis for dead cells by using a fixable viability dye e-Fluor 780 (eBioscience). We observed a modest increase in dead cells in cultures with dexamethasone, cytokines, and cytokines plus dexamethasone. The difference in dead cell numbers among these cultures was not significant. Fig 1, A) , and then IL-5 1 cells (Fig 1, B) . We found that dexamethasone potently inhibited IL-5 1 ILC2s from Aspergillus species-and IL-2/IL-33-stimulated cultures. However, dexamethasone was less effective in inhibiting IL-5
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ILC2s from IL-2/IL-7/IL-33-stimulated cultures (Fig 1, B) . We performed a similar experiment with dexamethasone using BAL fluid cells from a patient with allergic asthma. Cells were cultured without IL-2/IL-7/IL-33. We observed negligible inhibition of BAL fluid IL-5 1 ILC2s (Fig 1, C) . We measured the effect of dexamethasone on BAL fluid cell viability using 2 viability dyes: the fixable viability dye eFluor 780 and the dye Zombie aqua. Both dyes stain dead cells. Dexamethasone caused a modest increase in dead cells in BAL fluid when stained with eFluor 780 but not when stained with Zombie aqua (see Fig E2, B and C). The clinical characteristics of the BAL fluid donors are shown in Table I . The patients had moderate-tosevere asthma, as defined by the Expert Panel Report 3 guidelines. Dexamethasone sensitivity (percentage inhibition of IL-5 1 cells) of BAL fluid ILC2s correlated negatively with BAL fluid eosinophils (r 5 20.77, P 5 .00003) and blood eosinophils (r 5 20.69, P 5 .003) but positively with baseline FEV 1 (r 5 0.58, P 5 .003) and FEV 1 /forced vital capacity ratio (r 5 0.51, P 5 .01; Table II ).
The IL-7Ra ligands IL-7 and TSLP induce steroid resistance in vitro Next, we examined the effect of various combinations of ILC2-stimulating cytokines on induction of steroid resistance in vitro. We found that the presence of IL-7 and TSLP, but not IL-25 or IL-33, in the cytokine combo was associated with development of steroid resistance (Fig 2, A) . IL-7 and TSLP attenuated dexamethasone inhibition of IL-5 1 ILC2s in the blood. Note that IL-2 was added to all cultures as an ILC growth factor. It did not make any difference for steroid resistance. Kinetics analysis showed that development of steroid resistance required a prolonged 5-day exposure to these cytokines (Fig 2, B) The effect of dexamethasone was measured by using 2 approaches: measurement of secreted IL-5 by means of ELISA and measurement of the expression of intracellular IL-5 by using flow cytometry. Dexamethasone inhibited IL-5 secretion by IL-2/ IL-33-stimulated ILCs by nearly 79% (Fig 2, C) . In contrast, it inhibited IL-5 secretion by IL-2/TSLP-stimulated ILCs by only 25%. Measurement of intracellular IL-5 in ILCs from the same experiment showed a similar result. Dexamethasone inhibited intracellular IL-5 expression in IL-2/IL-33-and IL-2/TSLPstimulated ILCs by 65% and 18%, respectively (Fig 2, D) .
We examined steroid resistance of IL-5 BAL fluid cells from these asthmatic patients were also steroid resistant (Fig 2, E) . However, their steroid resistance was milder when compared with the steroid resistance of ILC2s. Note that the frequency of IL-5 The foregoing experiments were performed with cells from asthmatic patients. In a next set of experiments, we examined the effect of dexamethasone on ILCs from healthy control subjects. PBMCs from healthy subjects had low numbers of CRTH2 1 ILC2s (see Fig E3, A, in this article's Online Repository at www.jacionline.org) and type 2 cytokine expression (see Fig E3, B) . Culture of these cells with IL-2/IL-33 and IL-2/TSLP marginally increased their cytokine expression. Dexamethasone inhibited IL-2/IL-33-but not IL-2/TSLPinduced IL-5 expression in ILC2s from healthy subjects (see Fig E3, C) . The results suggest that TSLP induces steroid resistance in ILC2s not only from asthmatic patients but also from healthy subjects.
TSLP levels are increased in BAL fluid from asthmatic patients and correlated with steroid resistance of ILCs Because BAL fluid ILC2s from asthmatic patients were relatively resistant to dexamethasone-mediated inhibition, we asked whether IL-7 and TSLP contributed to this resistance. We examined levels of IL-7 and TSLP in BAL fluid from asthmatic patients. IL-7 was largely undetectable (data not shown). In contrast, we detected higher levels of TSLP in BAL fluid from asthmatic patients compared with those in control subjects with disease (Fig 3, A) . We examined the relevance of TSLP for ILC2 steroid resistance. TSLP levels negatively correlated with dexamethasone inhibition of BAL fluid IL-5 1 ILC2s (Fig 3, B) .
TSLP is synergistically induced by IL-13 and human rhinovirus-16
Next, we examined TSLP expression by human airway epithelial cells cultured at the air-liquid interface. Initially, we studied TSLP mRNA induction by the type 2 cytokine IL-13, the type 1 cytokine IFN-g, the Toll-like receptor 4 agonist LPS, and the Toll-like receptor 3 agonist poly-IC. IL-13 and poly-IC induced the expression of TSLP mRNA (Fig 3, C) . Because poly-IC is a viral mimic, we examined the effect of human rhinovirus with and without IL-13 on TSLP production at the protein level. We chose rhinovirus because it is a frequent cause of asthma exacerbation. 17 Human rhinovirus-16 induced modest TSLP production, which was synergistically augmented by IL-13 (Fig 3, D) .
Dexamethasone strongly induces IL-7Ra on ILC2s
We studied the mechanism of IL-7 and TSLP induction of steroid resistance. We cultured PBMCs in the presence or absence of dexamethasone. Dexamethasone inhibited the frequency of CRTH2
1 ILCs but strongly upregulated the frequency of 
IL-7Ra
1 ILCs (Fig 4, A-C) . More importantly, it increased the cell expression level (mean fluorescence intensity) of IL-7Ra (Fig 4, D) . Because most of our asthmatic patients are taking inhaled steroids and some are taking systemic steroids, we compared IL-7Ra
1 Lin 2 cells in the blood and BAL fluid. We found increased numbers of IL-7Ra 1 cells in BAL fluid (Fig 4,  E) . We recognize that this increase could be due to a number of reasons, which include the underlying disease process and treatment with steroids. We examined the effect of dexamethasone with and without cytokines (IL-7 and TSLP) on expression of the IL-2 receptor CD25, the IL-25 receptor, and the IL-33 receptor (ST2). Dexamethasone with and without the cytokines had negligible effects on expression of these receptors on ILC2s (see Fig E4 in this article' s Online Repository at www.jacionline.org).
IL-7Ra is the common receptor for IL-7 and TSLP. 18 The increase in IL-7Ra levels raised an intriguing possibility that IL-7 and TSLP signaling was altered in dexamethasone-treated cells, which contributed secondarily to steroid resistance. To test this hypothesis, we cultured cells with vehicle or dexamethasone for 3 days and then stimulated them with IL-2/ TSLP for an increasing period of time. We monitored levels of pSTAT5, which is a major signaling molecule downstream of IL-7Ra. Dexamethasone-pretreated cells showed a significantly higher frequency of pSTAT5 1 cells (Fig 4, F) . Furthermore, this increased pSTAT5 level was sustained over a longer period of time compared with that seen in vehicle-treated cells.
Dexamethasone is less effective in suppressing MEK1 and signal transducer and activator of transcription 5 signaling in the presence of TSLP In a next set of experiments, we examined the signaling mechanism that contributed to steroid resistance of ILC2s. We previously reported that MEK1 (referred to as MEK) conferred steroid resistance to T cells. 4 MEK translocated to the nucleus, interacted with the GR corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT), and induced its nuclear export. 19 MEK also directly bound to the c-Fos promoter. Recently, a functional genomics study using short hairpin RNA against all known genes identified MEK2 and MEK4 as top inducers of steroid resistance in leukemic cells. 20 MEK is expressed at low levels in quiescent cells and is upregulated on stimulation. 11 We examined the induction of MEK by ILC2-regulating cytokines in the presence and absence of dexamethasone. Note that dexamethasone and the cytokines were added simultaneously to the culture for these experiments. IL-2/IL-33 and IL-2/TSLP increased MEK expression in ILC2s (Fig 5, A) . Dexamethasone caused a near-complete inhibition of MEK induction by IL-2/IL-33 but only modestly affected the induction by IL-2/TSLP. Fig 5, B, shows cumulative data on MEK suppression by dexamethasone from 7 asthmatic patients. The results show that dexamethasone was a stronger inhibitor for IL-33 than for TSLP in suppressing MEK.
MEK activates extracellular signal-regulated kinase (ERK) 1/2 and induces c-Fos among many other genes. c-Fos, a component of the activator protein 1 complex, has previously been shown to antagonize GR at the transcriptional level. 21 We examined c-Fos induction in ILC2s by IL-2/IL-33 and IL-2/TSLP. Dexamethasone caused a dramatic inhibition of c-Fos induction in ILC2s stimulated with IL-2/IL-33 and IL-2/TSLP (Fig 5, C, and see Fig E5, A, in this article's Online Repository at www.jacionline.org).
Signal transducer and activator of transcription (STAT) 5 is another signaling molecule that induces steroid resistance.
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STAT5 binds to the GR and sequesters it in the cytosol. We examined the effect of dexamethasone on pSTAT5 induction in ILC2s. Dexamethasone was effective in inhibiting IL-2/IL-33-induced but not IL-2/TSLP-induced pSTAT5 (Fig 5, D) . MEK and STAT5 are known to regulate each other. 23 Treatment with the MEK inhibitor trametinib significantly inhibited pSTAT5 induction by IL-2/IL-33 and IL-2/TSLP (Fig 5, E) . This suggested that MEK functioned upstream of STAT5. We examined whether TSLP and IL-33 differentially affected GR expression on ILC2s on culture. ILC2s expressed high levels of GR (Fig 5, F) . TSLP did not alter GR expression when compared with IL-33.
Next, we studied the effect of dexamethasone on MEK and pSTAT5 in BAL fluid ILC2s from asthmatic patients. Dexamethasone was unable to inhibit MEK and pSTAT5 in BAL fluid ILC2s (Fig 6, A and B) . TSLP is known to activate STAT3. 24 Interestingly, pSTAT3 expression in BAL fluid ILC2s was susceptible to dexamethasone-mediated inhibition (Fig 6,  C, and see Fig E5, B) . ILC2s express ID3, a transcription factor involved in developmental processes of lymphocytes. 25 ID3 is positively regulated by the MEK-ERK signaling pathway and induces steroid resistance. 26 We examined ID3 expression by BAL fluid ILC2s in the presence and absence of dexamethasone. Dexamethasone significantly inhibited ID3 expression in BAL fluid ILC2s (Fig 6, D, and see Fig E5, C) .
Because MEK seems to play an important role in steroid resistance of ILC2s, we asked whether its levels were higher in BAL fluid ILCs compared with those in blood ILCs. For this purpose, we studied BAL fluid and blood ILCs from the same patients (n 5 4). A small fraction of BAL fluid ILCs studied ex vivo expressed MEK (see Fig E6, A and B, in this article's Online Repository at www.jacionline.org). In contrast, blood ILCs expressed very little MEK. The difference in MEK levels between BAL fluid and blood was statistically significant. Blood ILCs increased their MEK expression when cultured in medium alone. This increase was further augmented on culture with IL-2/TSLP (see Fig E6, C) .
Inhibition of MEK and STAT signaling reverses steroid resistance
To establish the relevance of MEK and STAT5 signaling in steroid resistance, we cultured BAL fluid cells with trametinib 27 and tofacitinib, 28 inhibitors of MEK and the Janus kinase (JAK)-STAT pathway, respectively. Both inhibitors reduced the frequency of IL-5 1 ILC2s (Fig 7, A and B) . More importantly, they reversed the steroid resistance of BAL fluid ILC2s. Because tofacitinib inhibits all STATs downstream of JAK, we examined the effect of the STAT5 inhibitor pimozide. 29 Pimozide inhibited the frequency of pSTAT5 1 cells, as well as IL-5 1 ILC2s, in BAL fluid (Fig 7, C and D) . It also reversed the steroid resistance of BAL fluid ILC2s. Both tofacitinib and pimozide were more effective than trametinib in inhibiting IL-5 1 ILC2s.
DISCUSSION
In this article we identified a selective, stimulus-specific pathway in ILC2s conveying lack of response to dexamethasone, a pathway that could be implicated in patients with steroidresistant asthma. We showed that IL-33-and IL-25-inducible IL-5 1 ILC2s in blood were sensitive to inhibition by dexamethasone. In contrast, IL-7-and TSLP-inducible IL-5 1 ILC2s were relatively steroid resistant. We elucidated the mechanism of development of this steroid resistance. Dexamethasone increased expression of IL-7Ra, which is the common receptor for IL-7 and TSLP. Increased IL-7Ra expression promoted heightened and sustained induction of pSTAT5 and MEK in ILC2s by TSLP. Sustained induction of pSTAT5 and MEK converted steroid-sensitive ILC2s into steroid-resistant cells. Pharmacologic inhibition of MEK and STAT5 signaling abrogated the steroid resistance of ILC2s.
Steroid resistance of mouse ILC2s was previously examined by Kabata et al. 13 Similar to human ILC2s, mouse ILC2s became steroid resistant on exposure to IL-7 and TSLP. The authors demonstrated the development of steroid resistance in a mouse model of allergic asthma, which was reversed by an anti-TSLP antibody and the STAT5 inhibitor pimozide. The results established an important role for the TSLP-STAT5 axis in steroid resistance of ILC2s in a mouse model of asthma.
There are differences in steroid resistance between mouse and human ILC2s. Mouse ILC2s became steroid resistant when cultured with IL-2. In contrast, human ILC2s remained steroid sensitive in the presence of IL-2. We believe that upregulation of IL-7Ra was critical for the development of steroid resistance in human ILC2s. This is supported by the finding that only IL-7Ra agonists but no other ILC2-stimulating cytokines were capable of inducing steroid resistance. Although IL-2 induces STAT5, this induction is of short duration and lower amplitude when compared with TSLP induction of STAT5 in dexamethasonetreated cells. This also goes along with the finding that the induction of steroid resistance required prolonged incubation with TSLP.
The effect of dexamethasone on lymphocytes has been studied by many laboratories. A microarray study showed that IL-7Ra was one of the top upregulated genes by dexamethasone in lymphocytes. 30 Consequently, dexamethasone actually increased and not reduced the survival of lymphocytes on stimulation with IL-7. In our study dexamethasone increased the number of IL-5 1 ILC2s in some asthmatic patients (Fig 2, B) . Other laboratories have reported similar positive effects of dexamethasone on lymphocytes. Dexamethasone increased the number of IL-5 1 lymphocytes in a mouse model of chronic asthma. 31 Dexamethasone also increased the differentiation of human T H 17 cells. 32 These findings suggest that glucocorticoids exert both antagonistic and protagonistic effects on the development and function of lymphocytes, including ILCs.
Steroids are the mainstay of anti-inflammatory therapy in asthmatic patients, yet a significant number of patients do not adequately respond to steroids. 12 Steroid resistance in asthmatic patients is likely to occur at multiple cellular levels. Steroids induce inflammatory cell apoptosis and inhibit their proliferation and cytokine production. A moderation of these anti-inflammatory effects has been reported for lymphocytes and monocytes obtained from patients with severe asthma. 10 This is the first report on steroid resistance of ILC2s from a group of patients with refractory asthma.
Many studies have delineated the mechanism of steroid resistance at the signaling and molecular levels. Steroid resistance of mononuclear cells can be induced in vitro with microbial J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 superantigens in an ERK1/2-dependent manner. 33 As mentioned previously, we reported induction of steroid resistance in T cells by MEK1, an upstream activator of ERK1/2.
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In addition to ERK1/2, the p38 mitogen-activated protein kinase promotes steroid resistance of cells by phosphorylating unliganded GR and sequestering it in the cytosol. 34 Both ERK1/2 and p38 mitogen-activated protein kinase induce c-Fos. Inhibition of c-Fos by dexamethasone in ILC2s suggests that the former is unlikely to be involved in steroid resistance of ILC2s. The ERK pathway induces ID3 in lymphocytes. ID3 confers steroid resistance through inhibition of the transcription factor SWI3-related gene 3. 26 We observed inhibition of ID3 by dexamethasone in BAL fluid ILC2s. Therefore we do not believe that this pathway is important for steroid resistance of ILC2s.
One of the mechanisms of transrepression of genes by GR is its interaction with SMRT. 35 The latter forms a multimolecular complex with histone deacetylases (HDACs). 36 GR uses SMRT to recruit HDACs to the target genes and causes deacetylation of the chromatin. As mentioned, MEK translocates to the nucleus, interacts with SMRT, and causes its nuclear export. 17, 37 The fact that the MEK inhibitor reversed steroid resistance yet c-Fos and ID3 were not involved in steroid resistance raises 2 possibilities: (1) another pathway downstream of ERK1/2 mediates steroid resistance and (2) MEK directly mediates steroid resistance through its interaction with SMRT. These possibilities need to be addressed in future studies. Direct interventions in HDAC function also induce steroid resistance. The phosphoinositide kinase d inhibits HDAC2, which leads to steroid resistance. 38 As mentioned previously, TSLP and IL-7 signal through STAT3 and especially through STAT5. 39 Both STAT3 and STAT5 have a complex relationship with GR. They can function as protagonists and antagonists at the transcriptional level depending on the cell type and culture milieu. 40 Activation of GR inhibits expression of mRNA for STAT5 and JAK3, the upstream activator of STAT5. 41, 42 STAT5 binds GR in the cytosol and prevents its nuclear translocation. 22 STAT5 knockdown reverses steroid resistance. In our study 2 clinically available drugs, the JAK-STAT inhibitor tofacitinib and the STAT inhibitor pimozide, strongly inhibited BAL fluid IL-5
1 ILC2s and reversed their steroid resistance. These findings suggest that STAT5 plays a critical role not only in induction of IL-5 1 ILC2s but also in development of steroid resistance. . P values were calculated by using the nonparametric Kruskal-Wallis test. Dex, Dexamethasone; V, vehicle.
Three epithelial cytokines, IL-25, IL-33, and TSLP, are now considered to play an important role in inception of a type 2 immune response, allergic sensitivity, and asthma. 43 Of these 3 cytokines, only TSLP, which is a dexamethasone-regulated IL-7Ra ligand, induced steroid resistance of ILC2s. Most asthmatic patients are steroid sensitive, and their symptoms are well controlled with inhaled steroids. However, they transiently develop steroid resistance during an asthma exacerbation and require systemic administration of a much higher dose of steroid. Viral infection, especially rhinovirus infection, is a frequent cause of asthma exacerbation. 17 Our finding that the combination of IL-13 and rhinovirus augments TSLP production by epithelial cells provides a mechanistic understanding of steroid resistance during asthma exacerbation. An anti-TSLP antibody has previously been shown to block allergen-induced bronchospasm in asthmatic patients. 44 Our results provide a rationale for a trial of the anti-TSLP antibody, trametinib, and especially, tofacitinib and pimozide in patients with steroidresistant asthma.
Clinical implications: ILC2s become steroid resistant on exposure to TSLP. TSLP correlates with the steroid resistance of BAL fluid ILC2s. ILC2-dependent steroid resistance in asthmatic patients might benefit from inhibitors of MEK-ERK kinase and signal transducer and activator of transcription 5. (Fig E2, B) and Zombie aqua (BioLegend; Fig E2, C) . 
